NCT00101920View on ClinicalTrials.gov

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions
Non-small Cell Lung CancerNeoplasm MetastasisLung Cancer
Interventions
DRUG

ABX-EGF

2.5 mg/kg by an infusion pump over one hour

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY